These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 6989947)

  • 1. The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus.
    Edwards MS; Nicholson-Weller A; Baker CJ; Kasper DL
    J Exp Med; 1980 May; 151(5):1275-87. PubMed ID: 6989947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-independent classical pathway-mediated opsonophagocytosis of type Ia, group B streptococcus.
    Baker CJ; Edwards MS; Webb BJ; Kasper DL
    J Clin Invest; 1982 Feb; 69(2):394-404. PubMed ID: 7035495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surface-bound capsular polysaccharide of type Ia group B Streptococcus mediates C1 binding and activation of the classic complement pathway.
    Levy NJ; Kasper DL
    J Immunol; 1986 Jun; 136(11):4157-62. PubMed ID: 3517165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci.
    Edwards MS; Kasper DL; Jennings HJ; Baker CJ; Nicholson-Weller A
    J Immunol; 1982 Mar; 128(3):1278-83. PubMed ID: 7035562
    [No Abstract]   [Full Text] [Related]  

  • 5. Opsonic specificity of human antibody to the type III polysaccharide of group B Streptococcus.
    Edwards MS; Baker CJ; Kasper DL
    J Infect Dis; 1979 Dec; 140(6):1004-8. PubMed ID: 396335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of L-ficolin/mannose-binding lectin-associated serine protease complexes in the opsonophagocytosis of type III group B streptococci.
    Aoyagi Y; Adderson EE; Min JG; Matsushita M; Fujita T; Takahashi S; Okuwaki Y; Bohnsack JF
    J Immunol; 2005 Jan; 174(1):418-25. PubMed ID: 15611266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth of group B streptococci in human serum leads to increased cell surface sialic acid and decreased activation of the alternative complement pathway.
    Platt MW; Correa N; Mold C
    Can J Microbiol; 1994 Feb; 40(2):99-105. PubMed ID: 8019940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation.
    Jarvis GA; Vedros NA
    Infect Immun; 1987 Jan; 55(1):174-80. PubMed ID: 3098684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A sialic-acid-specific lectin from Cepaea hortensis that promotes phagocytosis of a group-B, type-Ia, streptococcal strain.
    Holm SE; Bergholm AM; Wagner B; Wagner M
    J Med Microbiol; 1985 Jun; 19(3):317-23. PubMed ID: 3892008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An alternative role for specific antibody in neutrophil bactericidal activity against highly pathogenic group B streptococci.
    Cleat PH; Coid CR
    Br J Exp Pathol; 1982 Aug; 63(4):452-7. PubMed ID: 6817779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of complement and antibody in opsonophagocytosis of type II group B streptococci.
    Baker CJ; Webb BJ; Kasper DL; Edwards MS
    J Infect Dis; 1986 Jul; 154(1):47-54. PubMed ID: 3519791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of complement component C1q in the IgG-independent opsonophagocytosis of group B streptococcus.
    Butko P; Nicholson-Weller A; Wessels MR
    J Immunol; 1999 Sep; 163(5):2761-8. PubMed ID: 10453019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunodeterminant specificity of human immunity to type III group B streptococcus.
    Kasper DL; Baker CJ; Baltimore RS; Crabb JH; Schiffman G; Jennings HJ
    J Exp Med; 1979 Feb; 149(2):327-39. PubMed ID: 84042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.
    Wessels MR; Paoletti LC; Kasper DL; DiFabio JL; Michon F; Holme K; Jennings HJ
    J Clin Invest; 1990 Nov; 86(5):1428-33. PubMed ID: 2243123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci.
    Marques MB; Kasper DL; Pangburn MK; Wessels MR
    Infect Immun; 1992 Oct; 60(10):3986-93. PubMed ID: 1398910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of antibody and complement in opsonization of group B streptococci.
    Shigeoka AO; Hall RT; Hemming VG; Allred CD; Hill HR
    Infect Immun; 1978 Jul; 21(1):34-40. PubMed ID: 101462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type III group B Streptococcus: functional interaction with IgG subclass antibodies.
    Givner LB; Baker CJ; Edwards MS
    J Infect Dis; 1987 Mar; 155(3):532-9. PubMed ID: 3543156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-dependent alternate pathway of complement activation in opsonophagocytosis of Porphyromonas gingivalis.
    Cutler CW; Kalmar JR; Arnold RR
    Infect Immun; 1991 Jun; 59(6):2105-9. PubMed ID: 2037371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of antibody concentration on opsonic requirements for phagocytosis in vitro of Streptococcus pneumoniae types 7 and 19.
    Chudwin DS; Wara DW; Lameris-Martin NB; Ammann AJ
    Proc Soc Exp Biol Med; 1983 Feb; 172(2):178-86. PubMed ID: 6402784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opsonization of Streptococcus agalactiae of bovine origin by complement and antibodies against group B polysaccharide.
    Rainard P; Boulard C
    Infect Immun; 1992 Nov; 60(11):4801-8. PubMed ID: 1398991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.